ClinicalTrials.gg
Not yet recruitingNCT06641024Updated Oct 15, 2024

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

A Phase 1 interventional study of MC-1-50 in Acute Lymphoblastic Leukemia, in Relapse and Refractory Acute Lymphoblastic Leukemia, sponsored by Chongqing Precision Biotech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Chongqing Precision Biotech Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
140th of 209
24 · median 45
Started
2024
with 34 others
Phase 1
66 of 232
31 open now
Primary completion
2027-11
later than 85 of 124 live
Registered
182nd of 232
by date

Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 140th largest by planned enrollment of the 209 interventional ones that give a count, is one of 35 that started in 2024, is one of 66 in phase 1, reaches primary completion later than 85 of the 124 other live ones, and was the 182nd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

108 more — sign in →

All 113 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B Cell Acute Lymphoblastic Leukemia.

Read the detailed description

Based on the specific CD19-targeting CAR-T developed on the PrimeCARTM platform, the cell preparation time is about 3 days, which can greatly shorten the waiting time of patients, improve production efficiency and reduce production costs. At the same time, MC-1-50 products have a high proportion of T naive cells, which can play a therapeutic effect at a very low infusion dose to improve safety. In this study, a \"3+3\" design was adopted, and three dose groups were set up with 1×10\^5/kg, 3×10\^5/kg, and 5×10\^5/kg CAR-positive cells, respectively (the upper limit of the total number of cells was not more than 5×10\^7 CAR-positive cells). All subjects received only one infusion of MC-1-50 cells.

03

Conditions studied

  • Acute Lymphoblastic Leukemia, in Relapse
  • Refractory Acute Lymphoblastic Leukemia

Keywords

  • B-ALL
  • CAR-T
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient or their guardian agrees to participate in this clinical trial and sign the ICF, indicating their understanding of the purpose and procedures of this clinical trial and willingness to participate in the study;
  2. Age ≥ 18 years old (including threshold), gender not limited;
  3. Diagnosed with B-cell acute lymphoblastic leukemia and meeting one of the following conditions:

    1. B-ALL: Early refractory patients who have not achieved complete remission of bone marrow after two courses of systemic therapy upon initial diagnosis;
    2. Relapsed B-ALL:

      ① Early relapsed after complete remission (\< 12 months);

      ② Late relapsed after complete remission (≥ 12 months) requires systemic therapy again, but if complete remission is not achieved or early treatment response is poor;

      ③ Having experienced 2 or more times bone marrow relapse;

      ④ Relapsed after hematopoietic stem cell transplantation;

    3. Individuals with Philadelphia chromosome positive (Ph+) disease are eligible if they have relapsed/refractory disease despite treatment with at least 2 different tyrosine kinase inhibitors (TKIs); (Note: Except for those who are intolerant to TKI therapy, or have T315i mutations);
  4. Flow cytometry confirms the expression of CD19 in leukemia cells in the bone marrow. In individuals previously treated with targeted CD19 antibodies (such as blinatumomab), the proportion of CD19 positive cells in leukemia cells must be ≥ 90%;
  5. Morphological disease in the bone marrow (≥ 5% blasts);
  6. score 0-1;
  7. Expected survival time of more than 12 weeks;
  8. Adequate renal, hepatic, pulmonary and cardiac function defined as:

    1. Cardiac function: Echocardiography indicates ≥ 50%;
    2. Renal function: serum creatinine ≤ 2.0 × , or rate ≥ 60ml/min (Cockcroft Gault formula);
    3. Hepatic function: and AST ≤ 3.0 × ULN (may be relaxed to ≤ 5.0 × ULN in cases of combined liver infiltration);
    4. Total ≤ 2.0 × ULN (Gilbert syndrome requires total bilirubin ≤ 3.0 × ULN);
    5. Pulmonary function: Blood oxygen saturation is ≥ 92% in non oxygen state.
  9. No serious mental disorders;
  10. Meet standards for apheresis or venous blood collection, and no other cell collection ;
  11. Women of childbearing age who have a negative blood pregnancy test and all subjects agree to use reliable and effective methods (excluding safe period contraception) for contraception within one year after receiving MC-1-50 cell infusion from the time of signing the form. Including but not limited to: abstinence, implantable progestogen contraceptives that can inhibit ovulation; Intrauterine device (IUD); Intrauterine hormone release system; Spouse vasectomy; Compound hormone contraceptives that can inhibit ovulation (oral, vaginal, and transdermal); Progesterone contraceptives (oral or injectable) that can inhibit ovulation; When male subjects have sex with fertile women, they must agree to use barrier contraception (such as condom plus spermicidal foam/gel/film/emulsion/suppository). At the same time, participants should commit not to donate eggs (oocytes, oocytes) or sperm for assisted reproduction within one year after cell infusion.

Exclusion criteria

Exclusion Criteria:

  1. Isolated extramedullary disease;
  2. Central nervous system abnormalities: defined as CNS-2 and 3 according to NCCN guidelines (note: CNS-2 and 3 can be screened, but must be treated and recovered to CNS-1 before lymphodepleting chemotherapy and infusion);
  3. Transformation of chronic myeloid leukemia to acute biphenotypic leukemia;
  4. Individuals who have received CAR-T therapy or other gene modified cell therapies;
  5. Prior to apheresis, the following anti-tumor treatments have been received: chemotherapy, targeted therapy, and other drug treatments within 14 days or at least 5 half lives (whichever is shorter); Received radiation therapy within 14 days;
  6. or HBcAb positive and HBV DNA is greater than the normal range; antibody is positive and HCV RNA greater than the normal range; antibody positive; syphilis positive; CMV DNA positive;HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive;
  7. Suffered from any of the following heart diseases:

    1. (NYHA) stage III or IV congestive heart failure;
    2. Within the 6 months prior to enrollment, there has been a myocardial infarction, or a coronary artery bypass grafting (CABG) or stent implantation surgery has been performed;
    3. History of ventricular arrhythmias requiring treatment or unexplained syncope (excluding cases caused by vasovagal or dehydration);
    4. History of severe non-ischemic cardiomyopathy;
  8. Uncontrollable infection in the 2 weeks before enrollment;
  9. Acute grade 2-4 (GVHD) or moderate to severe chronic GVHD within the first 4 weeks of enrollment;
  10. If a cerebrovascular accident or seizure occurs within the first 6 months of enrollment;
  11. Active diseases;
  12. Deep vein or deep artery embolism event within the past 6 months prior to enrollment;
  13. Poor control of hypertension during screening is defined as systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg (blood pressure values are measured based on the average of three readings taken at least 2 minutes apart. Patients with blood pressure ≥ 160/100mmHg at the initial screening can receive antihypertensive treatment, and if good control is achieved after treatment and blood pressure\<160/100mmHg, enrollment can be performed);
  14. History of other than fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, local prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery;
  15. (attenuated) ≤ 4 weeks prior to enrollment;
  16. Have participated in other clinical trials within one month or five drug half lives (whichever is shorter) before enrollment;
  17. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving MC-1-50 cell infusion;
  18. Other situations considered by the investigator to be unsuitable to participate in the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    MC-1-50

    Patients will be be treated with CD19 CAR- T cells

    Biological: MC-1-50

Interventions

  • BiologicalMC-1-50

    A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Dose-limiting toxicity after CD19 CAR-T cell infusion

    Time frame: 1 month

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The incidence of adverse events after CAR-T cell infusion was assessed by the National Cancer Institute\&#39;s Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)

    Time frame: 1 month

Secondary outcomes

  1. AUCS of MC-1-50 cells [Cell dynamics]

    AUCS is defined as the area under the curve in 90 days

    Time frame: 3 months

  2. CMAX of MC-1-50 cell preparation [Cell dynamics]

    CMAX is defined as the highest concentration of MC-1-50 cells expanded in peripheral blood

    Time frame: 3 months

  3. TMAX of MC-1-50 cell preparation[Cell dynamics]

    TMAX is defined as the time to reach the highest concentration

    Time frame: 3 months

  4. Pharmacodynamics of MC-1-50 cell preparation[Cell dynamics]

    The clearance degree of CD19-positive B cells in peripheral blood was detected by flow cytometry at the visit points specified in the research protocol

    Time frame: 3 months

  5. Immunogenicity of pCAR-19B cells

    The anti-CAR antibody was detected by ELISAt the visit points specified in the research protocol

    Time frame: 3 months

  6. Objective response rate after MC-1-50 infusion [Efficacy]

    Objective response rate after pCAR-19B infusion \[Efficacy\]

    Time frame: 3 months

Other outcomes

  1. Objective response rate after MC-1-50 infusion [Long-term Efficacy]

    Objective response rate includes CR, CRi

    Time frame: 2 years

  2. Duration of Response (DOR) after MC-1-50 infusion [Long-term Efficacy]

    DOR will be assessed from the first assessment of CR/PR to the first assessment of recurrence or progression of the disease or death from any cause

    Time frame: 2 years

  3. Progress-free survival(PFS) after MC-1-50 infusion [Long-term Efficacy]

    PFS will be assessed from the first MC-1-50 cell infusion to death from any cause or the first assessment of progression

    Time frame: 2 years

  4. Event-Free survival(EFS) after MC-1-50 infusion [Long-term Efficacy]

    EFS will be assessed from the first MC-1-50 cell infusion to death from any cause or Disease progression or Treatment failure

    Time frame: 2 years

  5. Overall survival(OS) after MC-1-50 infusion [Long-term Efficacy]

    OS will be assessed from the first MC-1-50 cell infusion to death from any cause

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Nov 2027, 36 months later.

Of 50 industry-sponsored phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 36 months is below that.

Counting every sponsor, half of 209 studies reached it within 57 months; a quarter within 35 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Oct 15, 2024
StartEst.
Nov 1, 2024
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2039
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06641024
Collaborators
Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2039 (estimated)
Last update
Oct 15, 2024

Study contacts

Jian qing Mi, M.D.
Contact
jianqingmi@shsmu.edu.cn
+8613524488296

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion